Figure 2.

Circulating hybrid cell (CHC) levels correlate with therapeutic response and resistance while on trial protocol−directed therapy. Longitudinal evaluation of all five patients demonstrates an initial decrease in CHC counts after treatment initiation; this response was sustained in Patients 2, 3, and 4 who ultimately demonstrated sustained evidence of treatment response by the end of trial. Patients 1 and 5 demonstrated evidence of treatment resistance by the end of trial, which temporally correlated with increasing CHC levels. HAI, hepatic arterial infusion; mFOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; mFOLFIRI, folinic acid, 5-flurouracil, irinotecan.